What Hurts Hospice Business Valuations?

Referral concentration, Medicare audit exposure, high caregiver turnover, and poor documentation are the four factors that most consistently damage hospice business valuations in 2026. A clean hospice with diversified referral sources and stable census commands 8.0x-12.5x EBITDA. The same revenue with a concentrated referral base and an active ADR letter might come in at 4.0x-5.0x — or not sell at all until the issues clear.

How Referral Concentration Destroys Hospice Multiples

Buyers in hospice M&A have a hard threshold: if more than 20-25% of your average daily census comes from a single facility, physician group, or referral source, they will apply a meaningful discount to the purchase price. Some will walk entirely. The reason is simple — that relationship could end the day the deal closes. The new owner inherits a dependency that the selling owner spent years building, and they have no guarantee it continues.

The fix is not complicated but it takes time. Spend 12-18 months before going to market systematically diversifying your admission sources across multiple hospital systems, skilled nursing facilities, assisted living communities, and community-based physicians. Track referral source concentration monthly and build relationships intentionally with sources that currently represent less than 5% of your census. By the time you go to market, you want no single source above 15% of admissions and your top five sources collectively representing less than 50% of census. That profile commands premium multiples because it demonstrates a sustainable, defensible referral network rather than a relationship-dependent operation.

How Medicare Audits and Staffing Issues Impact Your Hospice Multiple

An active Medicare ADR (Additional Development Request) is a deal killer in hospice M&A — full stop. Buyers cannot underwrite documentation risk they cannot quantify, and most institutional buyers will walk or hold the transaction until the audit resolves. If you have active ADR activity, the practical advice is to engage a healthcare compliance attorney, work through the audit process, and wait until you have a clean resolution before engaging the market.

High caregiver turnover — losing more than 50% of clinical staff annually — is the second major staffing signal that suppresses valuations. It tells buyers that the operation is unstable and will require significant investment in recruitment and training post-close. Turnover above 40% consistently shows up in due diligence, and buyers build a cost adjustment into their offer to account for the expected stabilization expense. Third, poor financial documentation — inconsistent billing records, undocumented census changes, informal financial statements — makes it nearly impossible to verify the earnings a buyer is paying for. A rigorous Quality of Earnings review will surface every inconsistency, and surprises at that stage kill deals or dramatically reset price expectations.

"Hospice sellers often come to me after they have already had a deal fall apart in due diligence. The issues that tanked those deals — concentrated referrals, pending audits, thin documentation — were almost always knowable and fixable 18 months earlier. I always encourage hospice owners to start the process with a pre-sale readiness review, not a buyer search. Getting the house in order first is what separates a 10x close from a 5x close." — John M. Salony

For a full picture of hospice business valuations, visit our Hospice industry hub. If you are also evaluating a home health component alongside your hospice operation, our Home Health Care business valuation guide covers closely related valuation dynamics and buyer expectations.